Gracell Biotechnologies PT Lowered to 11.00 at Citigroup

About 67% of Gracell Biotechnologies' investor base is looking to short. The analysis of current outlook of investing in Gracell Biotechnologies suggests that many traders are alarmed regarding Gracell Biotechnologies' prospects. Gracell Biotechnologies' investing sentiment shows overall attitude of investors towards Gracell Biotechnologies.
  
Gracell Biotechnologies had its price objective lowered by Citigroup from 12.00 to 11.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Other equities research analysts also recently issued research reports about the stock. BTIG Research upped their

Read at thelincolnianonline.com
news
  

Gracell Biotechnologies Fundamental Analysis

We analyze Gracell Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Short Ratio

Short Ratio Comparative Analysis

Gracell Biotechnologies is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Gracell Biotechnologies Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gracell Biotechnologies stock to make a market-neutral strategy. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with similar companies.

Peers

Gracell Biotechnologies Related Equities

CTMXCytomX Therapeutics   129.03   
0%
100.0%
ERASErasca   13.01   
0%
10.0%
CHRSCoherus BioSciences   5.15   
0%
3.0%
GLUEMonte Rosa   4.40   
0%
3.0%
DSGNDesign Therapeutics   3.43   
0%
2.0%
BPMCBlueprint Medicines   3.23   
0%
2.0%
BOLTBolt Biotherapeutics   2.78   
0%
2.0%
INZYInozyme Pharma   2.61   
0%
2.0%
ASMBAssembly Biosciences   0.90   
0%
1.0%
AMLXAmylyx Pharmaceuticals   0.22   
1.0%
0%
TERNTerns Pharmaceuticals   0.66   
1.0%
0%
XFORX4 Pharmaceuticals   0.89   
1.0%
0%
SPROSpero Therapeutics   1.61   
1.0%
0%
ABOSAcumen Pharmaceuticals   2.00   
1.0%
0%
NXTCNextCure   4.44   
3.0%
0%
DAWNDay One   4.59   
3.0%
0%
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios